Aug 2026· Computational biology and chemistry· Vol 126 Pt 1, pp.
109349
· 0 citations· 33 references
Medicine
Abstract
Background
Endometriosis affects approximately 10% of reproductive-age women, with a diagnostic delay of 7-10 years. Despite clinical heterogeneity, current rASRM staging poorly predicts treatment outcomes. Molecular subtyping may reveal biologically meaningful patient strata that complement anatomical staging.
Objective
To identify molecular subtypes of endometriosis through integrated bioinformatics and construct machine learning (ML)-based diagnostic and prognostic models.
Methods
Gene expression data from EndometDB (GSE141549; 89 endometriosis patients, 41 controls) were processed. Differentially expressed genes (DEGs), weighted gene co-expression network analysis (WGCNA), and protein-protein interaction (PPI) networks were integrated to identify core genes. Consensus clustering defined molecular subtypes. ML diagnostic (XGBoost, ensemble) and prognostic (random survival forest) models were constructed and validated by nested cross-validation. An exploratory treatment response model was additionally evaluated.
Results
823 DEGs (496 upregulated, 327 downregulated), 173 core genes, and 2 molecular subtypes were identified. Subtypes showed distinct ssGSEA pathway profiles but no statistically significant differences in rASRM score (p = 0.641) or age, suggesting molecularly-defined rather than clinically-defined heterogeneity. The ensemble diagnostic model achieved AUC= 0.892 (5-fold nested cross-validation). The random survival forest prognostic model, based on a surrogate endpoint, demonstrated an OOB concordance index of 0.751. An exploratory treatment response model performed no better than chance (AUC = 0.492).
Conclusions
Integrating multi-method bioinformatics with ML identified 2 distinct endometriosis molecular subtypes and yielded internally validated diagnostic and prognostic models, providing an analytical framework and candidate molecular targets for future studies of endometriosis heterogeneity.
Findings indicate that NUSAP1 is a novel immunohistochemical marker with high specificity that can serve as an important complement to existing markers such as Cyclin D1 and BCOR, providing a new practical tool for the precise pathological diagnosis of HGESS.
Cheng Wang, Yuling Kou, Jing Zeng et al.· Archives of Pathology &...· 0 citations
Background Crohn’s disease (CD) is a chronic inflammatory bowel disease with rising global incidence. Its multifactorial etiology involves genetic, environmental, microbial, and immunological factors. Current diagnostic methods are invasive and costly, underscoring the need for improved biomarkers and non-invasive tool...
Pei-Hong Li, Si-Qing Guo, Hong-Yi Hu et al.· Frontiers in Immunology· 0 citations
The Cancer Genome Atlas (TCGA) molecular classification of endometrial cancer (EC) into POLEmut, MMRd, p53abn, and NSMP subtypes has substantially improved prognostic stratification. However, molecular classification typically depends on sequencing, whereas surrogate clinical workflows combine immunohistochemistry (IHC...
Dhafer G. Honi, H. Jebur, László Szathmáry· 2026 IEEE 4th Conference on...· 0 citations
In‑vitro experiments demonstrated that SLC12A8 modulates proliferation, invasion, and migration in both EM and EAOC cell lines, and support SLC12A8 as a candidate functional mediation and potential biomarker linked to EM‑EAOC pathological progression, thereby extending the mechanistic understanding of these disorders.
Neuroblastoma (NB) exhibits profound clinical and molecular heterogeneity, highlighting the need for reproducible biomarkers for disease stratification. This study aimed to identify robust stage-associated gene signatures through integrative machine learning (ML) and cross-platform validation. Four independent NB micro...
Daniel Liu, Jimmy Kuo, Yao Wu et al.· Computational biology and ch...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.